Loading…
← CockpitCompetitor Analysis › 600566.SS HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class AOpen in the cockpit ↗

HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A600566.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese pharma company known for pediatric and OTC medicines, including cold/fever remedies for children.

Momentum leader 99
Mkt cap
$4.36B
US dollars, full cap
Free float
37%
of shares outstanding
$/day
$38.0M
20-day average traded
Fwd P/E
16.2×
forward earnings
ROIC−WACC
+36.8 pp
WACC 5.0%
Hurdle
-10 pp
Req g minus delivered
Next earnings
145 days
12 Apr 2027
Close · CNYCN¥31.58
1D+1.3%
1W+7.0%
1M+18.3%
3M+26.3%
6M+11.8%
YTD+20.1%
1Y+25.1%
ATR %2.9%
52w lowhigh0.2% off high

What HUBEI JUMPCAN PHARMACEUTICAL does

Chinese pharma company known for pediatric and OTC medicines, including cold/fever remedies for children.

Products and services

  • Pediatric OTC medicines
  • Prescription generics

Customers

  • Pharmacies/consumers (OTC)
  • Hospitals

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • OTC/pediatric medicines

What could go right

  • OTC/self-medication market growth

What could go wrong

  • OTC price competition
  • Centralized procurement for prescription lines

Moat: narrow (brand). Recognized consumer brand in China's pediatric OTC medicine segment.

Headquarters: Hubei, China · Employees: 4,137

Named competitors

HUBEI JUMPCAN PHARMACEUTICAL at a glance

Size HUBEI JUMPCAN PHARMACEUTICAL (600566.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $4.36B, the 554th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥31.58 on 18 Nov 2026.

Performance Over six months the shares gained 11.8%, against +0.8% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 20 in its peer set.

Growth Revenue fell 3.6% over the last twelve months (peer median +10.2%); the operating margin is 31.7% (peer median 15.7%).

Valuation It trades at 16.2× forward earnings against a peer median of 31.1× (4th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 36.8 points above its cost of capital (5.0% WACC).

Next results Next results expected around 12 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026600566.SS 114Peer median 103
Six months, rebased to 100: HUBEI JUMPCAN PHARMACEUTICAL against the median of its 20 peers (local-currency closes).

HUBEI JUMPCAN PHARMACEUTICAL financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥5.92BCN¥6.14BCN¥7.92BCN¥9.51BCN¥8.86B
Revenue growth—-22%-17%+7%—
Gross profitCN¥4.96BCN¥4.71BCN¥6.14BCN¥7.60BCN¥7.19B
EBITDAn/aCN¥2.16BCN¥2.73BCN¥3.19BCN¥2.57B
Net incomeCN¥1.82BCN¥1.78BCN¥2.53BCN¥2.82BCN¥2.17B
Free cash flowCN¥1.47BCN¥1.29BCN¥2.09BCN¥3.24BCN¥2.44B
Capital expenditureCN¥260MCN¥95.9MCN¥174MCN¥302MCN¥244M
Total debtCN¥1.44BCN¥912MCN¥1.16BCN¥1.58BCN¥733M

Quarterly statements and history in the cockpit →

HUBEI JUMPCAN PHARMACEUTICAL competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-25%0%+25%CAMXAJANTPHARM002294600332IONS4536000100EMCUREDFTXGLAXO128940TVTXERAS600085688336IPCALAB326030600566.SS6-month return →1-month return →
Up and to the right = strong over both horizons. HUBEI JUMPCAN PHARMACEUTICAL is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%20×30×40×CAMXAJANTPHARM0022946003324536000100EMCUREGLAXO128940TVTX600079600085688336IPCALABPTCT326030600566.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. HUBEI JUMPCAN PHARMACEUTICAL is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%+100%0%50%100%CAMXAJANTPHARM0022946003324536EMCUREGLAXOTVTX301569600079688336PTCT326030600566.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. HUBEI JUMPCAN PHARMACEUTICAL is the large dot.

HUBEI JUMPCAN PHARMACEUTICAL competitors and peer comparison

Head to head with its named competitors (600566.SS vs 000999.SZ vs 600750.SS vs 600332.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
HUBEI JUMPCAN PHARMACEUTICAL 600566.SS$4.36B+12%-4%32%16.2×-9.9%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ$6.59B+6%+4%14%13.2×-6.2%
China Resources Jiangzhong Pharmaceutical 600750.SS$2.27B+4%-10%24%16.5×-1.9%
Guangzhou Baiyunshan Pharmaceutical 600332.SS$4.45B-13%+1%3%12.9×-0.7%

How HUBEI JUMPCAN PHARMACEUTICAL compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

HUBEI JUMPCAN PHARMACEUTICAL against its 20 peers (data as of 18 Nov 2026)
Measure600566.SSPeer medianRank in peer set
1-month return+18.3%-2.9%3rd highest of 21
6-month return+11.8%+0.8%7th highest of 20
Distance from 52-week high-0.2%-32.7%highest of 21
Revenue growth (TTM)-3.6%+10.2%3rd lowest of 19
Operating margin31.7%15.7%5th highest of 19
Forward P/E16.2×31.1×4th cheapest of 17
Growth the price implies (Req g, 7 yrs)-9.9%7.3%least demanding of 17
Growth delivered (Del g)+0.3%+10.9%lowest of 17
Hurdle (Req g minus delivered)-10.1 pp-3.7 pp6th least demanding of 17
ROIC minus cost of capital+36.8 pp+4.9 pp2nd highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
Shenzhen Salubris Pharmaceuticals 002294.SZChina$4.31B-24%+14%11%35.4×12.4%+9.7%
Guangzhou Baiyunshan Pharmaceutical 600332.SSChina$4.45B-13%+1%3%12.9×-0.7%+4.7%
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
Santen Pharmaceutical 4536.TJapan$4.14B+10%+2%16%16.7×-5.0%+3.2%
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%40.4×n/an/a
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%15.0×4.7%+7.5%
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%n/a57.4%+3.1%
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%39.9×0.9%+45.1%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%

Questions

Who are HUBEI JUMPCAN PHARMACEUTICAL's main competitors?
Named competitors: China Resources Sanjiu Medical & Pharmaceutical (000999.SZ), Jiangzhong Pharmaceutical (600750.SS), Guangzhou Baiyunshan Pharmaceutical (600332.SS). The cockpit's measured peer set (industry) also includes Camurus (CAMX.ST), Ajanta Pharma (AJANTPHARM.NS), Shenzhen Salubris Pharmaceuticals (002294.SZ), Guangzhou Baiyunshan Pharmaceutical (600332.SS), Ionis Pharmaceuticals (IONS), Santen Pharmaceutical (4536.T).
Is HUBEI JUMPCAN PHARMACEUTICAL expensive compared with its peers?
On forward p/e it trades at 16.2× against a peer median of 31.1×, 4th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has HUBEI JUMPCAN PHARMACEUTICAL stock performed?
Over six months to 18 Nov 2026 the shares returned +11.8% against +0.8% for the median peer; over one year +25.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.